Published on 30 Jul 2022 on Benzinga via Yahoo Finance
Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook
View more earnings on CTLT
See more from Benzinga
Erytech's Battle With Activist Investor Echoes As Pherecydes Pharma Merger Vote Comes Closer
In February, Erytech Pharma SA (NASDAQ: ERYP) announced its proposed combination with Pherecydes ...
Erytech Pharma SA Sponsored ADR (ERYP) Upgraded to Buy: Here's Why
Erytech Pharma SA Sponsored ADR (ERYP) could be a solid choice for investors given its recent upg...
Erytech (ERYP) Stops Developing Drug in Leukemia, Down 19.6%
Shares of Erytech Pharma ERYP fell 19.6% on Aug 25 after management announced that it would no lo...
Erytech Pharma Culls Work On Late-Stage Leukemia Asset, Evaluates Partnership Options
Erytech Pharma SA (NASDAQ: ERYP) will no longer seek approval for Graspa in hypersensitive acute ...
Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook
View more earnings on CTLT See more from Benzinga
3 Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
Catalent, Inc. CTLT is well-poised for growth in the coming quarters, backed by its robust facili...
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
Catalent, Inc. CTLT is well-poised for growth in the coming quarters, backed by its robust facili...
Catalent's (CTLT) Latest Facility Expansion to Boost Capacity
Catalent, Inc. CTLT announced that it commenced a $175-million project to expand its flagship U.S...
Catalent's (CTLT) New Launch to Enhance Gene Therapy Development
Catalent, Inc. CTLT has recently introduced its new UpTempo Virtuoso platform process. The platfo...
71 Biggest Movers From Yesterday
Evoke Pharma, Inc. (NASDAQ: EVOK) shares jumped 118.5% to close at $0.86 on Tuesday. The FDA gran...